184 related articles for article (PubMed ID: 31288974)
21. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
[TBL] [Abstract][Full Text] [Related]
22. Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.
Glass OM; Hermida AP; Hershenberg R; Schwartz AC
Curr Psychiatry Rep; 2020 Apr; 22(5):21. PubMed ID: 32285305
[TBL] [Abstract][Full Text] [Related]
23. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
24. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
Choe YM; Kim KW; Jhoo JH; Ryu SH; Seo EH; Sohn BK; Byun MS; Bak JH; Lee JM; Yun HJ; Han MI; Woo JI; Lee DY
Int J Geriatr Psychiatry; 2016 Jul; 31(7):731-9. PubMed ID: 26553313
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
[TBL] [Abstract][Full Text] [Related]
26. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.
Scharre DW; Davis RA; Warner JL; Chang SI; Beversdorf DQ
Am J Geriatr Psychiatry; 2003; 11(6):687-91. PubMed ID: 14609811
[TBL] [Abstract][Full Text] [Related]
27. Principal components analysis of agitation outcomes in Alzheimer's disease.
Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
[TBL] [Abstract][Full Text] [Related]
28. Commentary on "When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram".
Pollock BG
Am J Geriatr Psychiatry; 2019 Oct; 27(10):1108-1109. PubMed ID: 31208921
[No Abstract] [Full Text] [Related]
29. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
Newell J; Yesavage JA; Taylor JL; Kraemer HC; Munro CA; Friedman L; Rosenberg PB; Madore M; Chao SZ; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
J Psychiatr Res; 2016 Mar; 74():17-21. PubMed ID: 26736036
[TBL] [Abstract][Full Text] [Related]
30. Calming Alzheimer's agitation: a promising drug.
Johns Hopkins Med Lett Health After 50; 2014 Jun; 29(5):8. PubMed ID: 25097959
[No Abstract] [Full Text] [Related]
31. Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia.
Spigset O; Wilhelmsson C; Mjörndal T; Eriksson S
Int Psychogeriatr; 2000 Dec; 12(4):537-45. PubMed ID: 11263719
[TBL] [Abstract][Full Text] [Related]
32. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
33. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic approach to management of agitation associated with dementia.
Kunik ME; Yudofsky SC; Silver JM; Hales RE
J Clin Psychiatry; 1994 Feb; 55 Suppl():13-7. PubMed ID: 7915710
[TBL] [Abstract][Full Text] [Related]
35. Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram.
Herrmann N
Evid Based Ment Health; 2016 Nov; 19(4):e24. PubMed ID: 27613071
[No Abstract] [Full Text] [Related]
36. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.
Pollock BG; Mulsant BH; Sweet R; Burgio LD; Kirshner MA; Shuster K; Rosen J
Am J Geriatr Psychiatry; 1997; 5(1):70-8. PubMed ID: 9169247
[TBL] [Abstract][Full Text] [Related]
37. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.
Salzman C; Jeste DV; Meyer RE; Cohen-Mansfield J; Cummings J; Grossberg GT; Jarvik L; Kraemer HC; Lebowitz BD; Maslow K; Pollock BG; Raskind M; Schultz SK; Wang P; Zito JM; Zubenko GS
J Clin Psychiatry; 2008 Jun; 69(6):889-98. PubMed ID: 18494535
[TBL] [Abstract][Full Text] [Related]
38. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
[TBL] [Abstract][Full Text] [Related]
39. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
[No Abstract] [Full Text] [Related]
40. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
